Related Experiment Video
Updated: Jul 29, 2026

Closure of a Patent Foramen Ovale (PFO): An Intervention Sequence
Published on: December 23, 2022
Patent ductus arteriosus: pathophysiology and management
E R Hermes-DeSantis1, R I Clyman
1Drug Information Service, Robert Wood Johnson University Hospital, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, New Jersey, USA.
Insights
Patent ductus arteriosus (PDA) in preterm infants presents treatment challenges. This review explores evidence and experience on optimal timing for indomethacin intervention to manage PDA and associated comorbidities.
Area of Science:
- Neonatalogy
- Pediatric Cardiology
Background:
- Patent ductus arteriosus (PDA) is common in preterm newborns (<28 weeks gestation).
- PDA can lead to increased pulmonary blood flow and affect organ perfusion.
- Associated comorbidities include necrotizing enterocolitis, intracranial hemorrhage, and bronchopulmonary dysplasia, though causality is debated.
Purpose of the Study:
- To review evidence and clinical experience regarding treatment strategies for PDA in preterm infants.
- To discuss the optimal timing for intervention, contrasting early prophylaxis with treatment upon symptom manifestation.
- To explore the comparative physiology of PDA closure in term versus preterm neonates.
Main Methods:
- Review of existing evidence and clinical experience.
- Discussion of prostaglandin inhibitor efficacy, specifically indomethacin.
- Analysis of physiological differences between term and preterm newborns concerning PDA closure.
Main Results:
- Indomethacin is an effective treatment for PDA.
- The optimal timing for intervention remains a significant clinical challenge.
- Understanding physiological barriers to PDA constriction in preterm infants is crucial.
Conclusions:
- Optimal timing for PDA intervention in preterm infants requires careful consideration of evidence and experience.
- Further research may clarify the causal role of PDA in neonatal comorbidities.
- Addressing PDA effectively is critical for improving outcomes in extremely preterm newborns.
Abstract:
Patent ductus arteriosus (PDA) in preterm newborns prior to 28 weeks of gestation has led to many challenges regarding the type and timing of treatment regimens. A PDA results in increased pulmonary blood flow and redistribution of flow to other organs. Several co-morbidities (i.e., necrotizing enterocolitis, intracranial hemorrhage, pulmonary edema/hemorrhage, bronchopulmonary dysplasia, and retinopathy) are associated with the presence of a PDA, but whether or not a PDA is responsible for their development is still unclear. The prostaglandin inhibitor, indomethacin, is effective in the treatment of PDA. Questions regarding the optimal timing of the intervention--early prophylaxis or treatment, once signs and symptoms become evident--have challenged physicians for decades. Both evidence and experience are explored in this article. Comparative physiology between the full-term and preterm newborn and the barriers preventing the necessary cascade of events leading to permanent constriction of the PDA are reviewed.
Related Concept Videos
Fetal Circulation
Two umbilical arteries transport blood from the fetus to the placenta. At the placenta, the blood absorbs oxygen and nutrients while simultaneously eliminating waste products. This oxygen-enriched and nutrient-rich blood then returns to the fetus through one...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Mitral Stenosis III: Medical Management
Aortic Regurgitation I: Introduction
Aortic Regurgitation III: Medical Management
Cardiomyopathy VII: Pre and Post Operative Nursing Management

